Cellyan Biotechnology CO Ltd HKPD

$0.10 -0.01 (-11.33%)

Valuation

Market cap: 1,715,000
Revenue TTM: $13,430,000
Net income TTM: $-1,140,000
PE ratio: 0.00
Forward PE: —
Profit margin: -8.49%
Debt to equity: 0.09

Trading

Volume: 87,522
Avg volume: 4,261,358
Day's range: $0.10 – $0.11
Shares out: 16,350,000
Stochastic %K: 96%
Beta: 2.57
Analysts: Strong Buy
Price target: —

Price

Company profile

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.

Industry: Medical Distribution
Sector: Healthcare
Phone: 852 2618 9289
Website: https://www.9zt.hk
Address: Well Town Industrial Building, Room B1, 5th Floor 13 Ko Fai Road, Yau Tong, Hong Kong

Latest news

Jul 16, 2026, 4:30 PM EDT · 3 months ago

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period

2026-06-12T20:36:06.000Z · 4 months ago

Cellyan Biotechnology files $200M mixed securities shelf

2026-03-27T19:25:14.000Z · 6 months ago

Cellyan Biotechnology Co. files to sell 12.5M Class A ordinary shares for holder

Jan 16, 2026, 4:30 PM EST · 9 months ago

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

Dec 17, 2025, 4:30 PM EST · 10 months ago

Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

Dec 1, 2025, 8:30 AM EST · 10 months ago

DCS Announces Q3 2025 Quarterly Financial Statements

Mar 28, 2025, 4:50 AM EDT · 1 year ago

Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

Jan 16, 2025, 2:10 PM EST · 1 year ago

Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering

2025-01-16T12:07:10.000Z · 1 year ago

Hong Kong Pharma announces pricing of 1.4M ordinary share IPO

2025-01-16T12:07:04.000Z · 1 year ago

Hong Kong Pharma opens at $3.50, IPO priced at $4 per share

Stocktwits

MalekJ Oct 14, 8:02 PM

$HKPD Has been in accumulation mode for some time.

0 replies

Mrdarky Oct 9, 10:31 AM

$HKPD this has a 2,7m float. It needs to RS soon which decreases the float further. Chinese microcap with huge potential to shoot to enormous heights soon. At the current price, it's nice to have a few thousand shares in your portfolio. And who knows, one day you open your broker app and you're rich $RETO $MI $JAGX

0 replies